Q3 2024 Genmab A/S Earnings Call Transcript
Key Points
- Genmab AS (GMAB) reported strong financial performance with a 37% increase in recurring revenues, driven by royalties from DARZALEX, Kesimpta, and other approved medicines.
- EPKINLY, a key product, showed robust growth with a 17% increase in net sales during Q3, highlighting its strong market uptake and competitive differentiation.
- The company successfully advanced its late-stage product portfolio, moving Rina-S and acasunlimab to Phase 3 trials, indicating progress in its pipeline development.
- Genmab AS (GMAB) achieved multiple regulatory approvals for its products, including EPKINLY's second approval in Europe and Tivdak's consistent quarter-over-quarter growth.
- The acquisition of Profound Bio enhanced Genmab AS (GMAB)'s long-term growth potential, adding next-generation ADC platforms to its portfolio.
- Genmab AS (GMAB) decided to terminate several early-stage clinical programs, including GEN1047, GEN3017, and Gen1056, indicating challenges in meeting internal benchmarks.
- The company will not proceed with Phase 3 development for Tivdak in second line plus head and neck cancer, reflecting strategic prioritization challenges.
- Operating expenses increased by 23% to approximately DKK9.9 billion, driven by R&D investments, which may impact short-term profitability.
- The effective tax rate experienced volatility, with a tax expense of around DKK1.6 billion, potentially affecting net profit margins.
- There is uncertainty regarding the HexaBody CD38 program, with data release contingent on J&J's opt-in decision, which could impact future strategic planning.
Hello, and welcome to Genmab's financial results conference call for the first nine months of 2024 As a reminder, this conference call is being recorded.
During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed all in successful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law.
Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Denmark going forward. Please refer to our website for more information on a and our privacy policy.
I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
- /
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
